18
Jan
2021
Blog
News & Views
Search
28
Dec
2020
Bionest
Is it COVID-19? Flu? Or Perhaps, Both?
With flu season rapidly approaching, concerns are growing about the risks of a double coronavirus-influenza pandemic that could further overwhelm hospitals and other health care resources.
14
Dec
2020
Bionest
Growing Competition for Hunter Syndrome Therapies
Hunter Syndrome has attracted a lot of interest from pharma, with trial therapies ranging from enzyme replacement and engineered drugs to gene and cell therapy approaches.
30
Nov
2020
Bionest
Emerging Applications of Artificial Intelligence in Cardiology
AI is making strides in cardiology, helping to enable quicker assessment & treatment of strokes, faster nuclear imaging & diagnostic radiology, and earlier detection & monitoring of heart disease.
11
Nov
2020
Bionest
Increased Focus on the Tumor Immune Environment
Researchers are looking to map and describe the workings of the tumor immune environment to find ways to potentiate an immune response or counteract immunosuppressive signals.
28
Oct
2020
Bionest
Time to Embrace Decentralized Clinical Trials
A clearer roadmap for decentralized clinical trials will enable companies to better plan and more quickly advance their adoption of these strategies, which have the potential of benefiting patients and drug developers alike.
6
Oct
2020
Bionest
Palforzia Benefit in Peanut Allergy Supported by New Data, While FDA Rejects Viaskin Peanut
The first commercial patients for peanut allergy oral therapy Palforzia have started treatment. How will its patch competitor fare?
21
Sep
2020
Bionest
Look Beyond the US and Europe for Rare Disease Launches
Rest-of-world markets offer good opportunities for rare disease companies to expand their sales potential beyond what U.S. & E.U. markets offer, and the requirements for market entry should be considered at a high level early on.
8
Sep
2020
Bionest
The Search for COVID-19 Biomarkers
There is an urgent need for effective biomarkers to help classify COVID-19 patients based on risk, so that aggressive monitoring and appropriate therapy can be promptly directed to those more likely to get more severe illness.
24
Aug
2020